Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$12.64
-2.8%
$10.92
$5.98
$13.66
$238.83M1.467,737 shs20,594 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$0.25
-10.6%
$0.29
$0.23
$2.23
$8.46M0.6303,481 shs12.16 million shs
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
$0.62
-0.2%
$0.61
$0.32
$0.65
$176.79M0.2214,848 shs4,900 shs
PAVmed Inc. stock logo
PAVM
PAVmed
$0.60
+0.2%
$0.65
$0.54
$1.90
$10.25M1.06137,063 shs113,531 shs
Beyond Air, Inc. stock logo
XAIR
Beyond Air
$0.20
-7.1%
$0.19
$0.15
$0.68
$16.84M0.221.56 million shs2.60 million shs
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
+1.01%+1.56%+18.07%+54.21%+111.73%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+0.54%-1.50%-5.50%-16.36%-77.10%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
+3.40%+2.85%+2.56%+26.61%+79.98%
PAVmed Inc. stock logo
PAVM
PAVmed
+8.01%+1.30%-6.77%-11.96%-23.24%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
+0.96%+18.11%+11.35%-8.70%-62.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
2.2151 of 5 stars
2.53.00.00.00.00.81.9
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
3.7118 of 5 stars
3.55.00.04.40.00.01.3
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
0.2419 of 5 stars
0.05.00.00.00.00.00.0
PAVmed Inc. stock logo
PAVM
PAVmed
4.3659 of 5 stars
3.55.00.04.30.00.01.9
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.9037 of 5 stars
3.73.00.03.51.10.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
3.00
Buy$14.2512.74% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
3.00
Buy$5.502,083.41% Upside
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
0.00
N/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
3.00
Buy$19.003,066.67% Upside
Beyond Air, Inc. stock logo
XAIR
Beyond Air
3.33
Buy$1.50669.23% Upside

Current Analyst Ratings Breakdown

Latest CODX, EDTXF, XAIR, BWAY, and PAVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/6/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.50 ➝ $19.00
4/28/2025
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/28/2025
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$10.00
4/21/2025
PAVmed Inc. stock logo
PAVM
PAVmed
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$19.00 ➝ $19.50
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$43.46M5.50$0.24 per share51.61$3.31 per share3.82
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$3.71M2.28N/AN/A$1.70 per share0.15
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
$1.67M105.86N/AN/A($0.07) per share-8.85
PAVmed Inc. stock logo
PAVM
PAVmed
$2.99M3.43N/AN/A($0.92) per share-0.65
Beyond Air, Inc. stock logo
XAIR
Beyond Air
$3.71M4.55N/AN/A$0.17 per share1.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$2.92M$0.2063.2079.00N/A9.01%7.35%4.72%8/5/2025 (Estimated)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$37.64M-$1.17N/AN/AN/A-1,025.45%-60.16%-52.69%8/6/2025 (Estimated)
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
-$11.24M-$0.07N/AN/A-1,078.10%N/A-336.97%8/7/2025 (Estimated)
PAVmed Inc. stock logo
PAVM
PAVmed
$39.79M$0.710.85N/AN/A3,711.54%N/A-42.29%8/12/2025 (Estimated)
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$46.62M-$0.79N/AN/AN/A-1,258.46%-233.96%-113.92%8/5/2025 (Estimated)

Latest CODX, EDTXF, XAIR, BWAY, and PAVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$0.07N/AN/AN/A$12.34 millionN/A
8/5/2025Q1 2026
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$0.08N/AN/AN/A$1.75 millionN/A
6/17/2025Q4 2025
Beyond Air, Inc. stock logo
XAIR
Beyond Air
-$0.14-$0.09+$0.05-$0.09$1.39 million$1.15 million
5/13/2025Q1 2025
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
$0.02$0.04+$0.02$0.04$11.45 million$11.54 million
5/9/2025Q1 2025
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/A-$0.03N/A-$0.03N/A$0.40 million
5/8/2025Q1 2025
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$0.33-$0.24+$0.09-$0.24$0.38 million$0.05 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/AN/AN/AN/AN/A
PAVmed Inc. stock logo
PAVM
PAVmed
N/AN/AN/AN/AN/A
Beyond Air, Inc. stock logo
XAIR
Beyond Air
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
N/A
5.03
4.75
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
4.43
4.23
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/A
0.09
0.08
PAVmed Inc. stock logo
PAVM
PAVmed
N/A
0.37
0.37
Beyond Air, Inc. stock logo
XAIR
Beyond Air
0.64
3.20
2.72

Institutional Ownership

CompanyInstitutional Ownership
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
30.11%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
N/A
PAVmed Inc. stock logo
PAVM
PAVmed
19.93%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
31.50%

Insider Ownership

CompanyInsider Ownership
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
19.00%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
8.40%
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
1.50%
PAVmed Inc. stock logo
PAVM
PAVmed
7.30%
Beyond Air, Inc. stock logo
XAIR
Beyond Air
19.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brainsway Ltd. Sponsored ADR stock logo
BWAY
Brainsway
12018.90 million15.31 millionNot Optionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
10033.57 million30.75 millionOptionable
Spectral Diagnostics Inc. stock logo
EDTXF
Spectral Diagnostics
29285.52 million281.24 millionNot Optionable
PAVmed Inc. stock logo
PAVM
PAVmed
9017.09 million15.85 millionOptionable
Beyond Air, Inc. stock logo
XAIR
Beyond Air
7086.37 million69.61 millionOptionable

Recent News About These Companies

Beyond Air Inc.
Beyond Air granted U.S. patent for gaseous nitric oxide delivery
Beyond Air Gets Patent for Lung Infection Treatment

New MarketBeat Followers Over Time

Media Sentiment Over Time

Brainsway stock logo

Brainsway NASDAQ:BWAY

$12.64 -0.36 (-2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$12.64 0.00 (0.00%)
As of 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$0.25 -0.03 (-10.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.25 +0.00 (+0.83%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Spectral Diagnostics stock logo

Spectral Diagnostics OTCMKTS:EDTXF

$0.62 0.00 (-0.19%)
As of 11:31 AM Eastern

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.

PAVmed stock logo

PAVmed NASDAQ:PAVM

$0.60 +0.00 (+0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$0.59 -0.01 (-1.17%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Beyond Air stock logo

Beyond Air NASDAQ:XAIR

$0.20 -0.02 (-7.14%)
Closing price 04:00 PM Eastern
Extended Trading
$0.19 0.00 (-1.03%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.